Do analysts rate ATXI or DCOY?

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, ATXI or DCOY?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is ATXI or DCOY more profitable?

Decoy Therapeutics' return on equity of -395.42% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Decoy Therapeutics N/A -395.42% -193.30%

Do analysts rate GOVX or ATXI?

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 20,414.22%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GOVX or ATXI more profitable?

Avenue Therapeutics' return on equity of -471.57% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% Avenue Therapeutics N/A -471.57% -296.50%

Is VCNX or ATXI more profitable?

Vaccinex's return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts rate GLMD or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, GLMD or ATXI?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$0.91 N/A Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A

Is GLMD or ATXI more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% Avenue Therapeutics N/A -471.57% -296.50%

Which has stronger valuation & earnings, VRAX or ATXI?

Virax Biolabs Group has higher revenue and earnings than Avenue Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 255.20 -$5.02M N/A N/A Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A

Is VRAX or ATXI more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Avenue Therapeutics N/A -471.57% -296.50%

Avenue Therapeutics (ATXI) Competitors

$0.28 +0.02 (+6.00%)

As of 07/24/2026 03:45 PM Eastern

Compare

ATXI vs. DCOY, GOVX, VCNX, GLMD, and VRAX

Should you buy Avenue Therapeutics stock or one of its competitors? MarketBeat compares Avenue Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avenue Therapeutics include Decoy Therapeutics (DCOY), GeoVax Labs (GOVX), Vaccinex (VCNX), Galmed Pharmaceuticals (GLMD), and Virax Biolabs Group (VRAX). These companies are all part of the "pharmaceutical products" industry.

How does Avenue Therapeutics compare to Decoy Therapeutics?

Avenue Therapeutics (NASDAQ:ATXI) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Decoy Therapeutics' return on equity of -395.42% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Avenue Therapeutics has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

In the previous week, Decoy Therapeutics had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for Decoy Therapeutics and 0 mentions for Avenue Therapeutics. Decoy Therapeutics' average media sentiment score of 1.44 beat Avenue Therapeutics' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Decoy Therapeutics	Positive

Summary

Decoy Therapeutics beats Avenue Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Avenue Therapeutics has lower revenue, but higher earnings than GeoVax Labs. Avenue Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.02	-$21.47M	-$19.12	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 20,414.22%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, GeoVax Labs had 4 more articles in the media than Avenue Therapeutics. MarketBeat recorded 4 mentions for GeoVax Labs and 0 mentions for Avenue Therapeutics. GeoVax Labs' average media sentiment score of 0.22 beat Avenue Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Neutral
Avenue Therapeutics	Neutral

Avenue Therapeutics' return on equity of -471.57% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Avenue Therapeutics	N/A	-471.57%	-296.50%

GeoVax Labs has a beta of 3.68, meaning that its stock price is 268% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

Summary

Avenue Therapeutics beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Avenue Therapeutics has lower revenue, but higher earnings than Vaccinex. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.91	-$20.25M	-$48.27	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Avenue Therapeutics	Neutral

Vaccinex's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

Summary

Vaccinex beats Avenue Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Avenue Therapeutics compare to Galmed Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Galmed Pharmaceuticals' return on equity of -35.32% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$0.91	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

Galmed Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

In the previous week, Galmed Pharmaceuticals had 4 more articles in the media than Avenue Therapeutics. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 0 mentions for Avenue Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.72 beat Avenue Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
Avenue Therapeutics	Neutral

Summary

Galmed Pharmaceuticals beats Avenue Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Virax Biolabs Group had 3 more articles in the media than Avenue Therapeutics. MarketBeat recorded 3 mentions for Virax Biolabs Group and 0 mentions for Avenue Therapeutics. Virax Biolabs Group's average media sentiment score of 1.24 beat Avenue Therapeutics' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Positive
Avenue Therapeutics	Neutral

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Virax Biolabs Group has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

Virax Biolabs Group's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Avenue Therapeutics	N/A	-471.57%	-296.50%

Virax Biolabs Group currently has a consensus target price of $25.00, suggesting a potential upside of 683.70%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virax Biolabs Group has higher revenue and earnings than Avenue Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	255.20	-$5.02M	N/A	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

Summary

Virax Biolabs Group beats Avenue Therapeutics on 11 of the 12 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATXI vs. The Competition

Export

Metric	Avenue Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$908K	$974.40M	$7.06B	$12.20B
Dividend Yield	N/A	4.84%	2.67%	9.41%
P/E Ratio	0.02	1.53	27.14	23.63
Price / Sales	N/A	109.45	582.30	111.98
Price / Cash	N/A	20.06	49.81	58.78
Price / Book	0.14	8.47	10.28	6.01
Net Income	-$10.38M	-$2.70M	$3.60B	$331.99M
7 Day Performance	10.24%	-2.29%	-1.27%	-0.63%
1 Month Performance	-1.57%	-4.64%	-1.67%	-3.04%
1 Year Performance	-30.61%	28.96%	18.25%	13.30%

Avenue Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATXI Avenue Therapeutics	N/A	$0.28 +6.0%	N/A	-30.6%	$908K	N/A	0.02	4	Gap Up
DCOY Decoy Therapeutics	3.0144 of 5 stars	$6.08 -1.6%	$30.00 +393.4%	N/A	$3.24M	N/A	N/A	20	Short Interest Decrease
GOVX GeoVax Labs	2.0899 of 5 stars	$0.90 -11.4%	$150.00 +16,659.8%	-96.3%	$3.11M	$852.28K	N/A	10	Positive News Upcoming Earnings Short Interest Increase Gap Down
VCNX Vaccinex	N/A	$1.16 flat	N/A	+66.2%	$3.02M	$388K	N/A	40	Gap Down
GLMD Galmed Pharmaceuticals	1.286 of 5 stars	$0.54 +5.4%	N/A	-74.2%	$3.01M	N/A	N/A	20	News Coverage Upcoming Earnings Short Interest Decrease High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avenue Therapeutics (ATXI) Competitors

ATXI vs. DCOY, GOVX, VCNX, GLMD, and VRAX

How does Avenue Therapeutics compare to Decoy Therapeutics?

Summary

How does Avenue Therapeutics compare to GeoVax Labs?

Summary

How does Avenue Therapeutics compare to Vaccinex?

Summary

How does Avenue Therapeutics compare to Galmed Pharmaceuticals?

Summary

How does Avenue Therapeutics compare to Virax Biolabs Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avenue Therapeutics (ATXI) Competitors

ATXI vs. DCOY, GOVX, VCNX, GLMD, and VRAX

How does Avenue Therapeutics compare to Decoy Therapeutics?

Do institutionals and insiders have more ownership in ATXI or DCOY?

Which has better valuation and earnings, ATXI or DCOY?

Do analysts rate ATXI or DCOY?

Is ATXI or DCOY more profitable?

Which has more risk & volatility, ATXI or DCOY?

Does the media refer more to ATXI or DCOY?

Summary

How does Avenue Therapeutics compare to GeoVax Labs?

Which has better valuation and earnings, GOVX or ATXI?

Do institutionals and insiders believe in GOVX or ATXI?

Do analysts rate GOVX or ATXI?

Does the media prefer GOVX or ATXI?

Is GOVX or ATXI more profitable?

Which has more risk & volatility, GOVX or ATXI?

Summary

How does Avenue Therapeutics compare to Vaccinex?

Do insiders and institutionals hold more shares of VCNX or ATXI?

Which has better earnings and valuation, VCNX or ATXI?

Does the media refer more to VCNX or ATXI?

Is VCNX or ATXI more profitable?

Which has more volatility and risk, VCNX or ATXI?

Summary

How does Avenue Therapeutics compare to Galmed Pharmaceuticals?

Do institutionals and insiders have more ownership in GLMD or ATXI?

Is GLMD or ATXI more profitable?

Do analysts rate GLMD or ATXI?

Which has stronger earnings & valuation, GLMD or ATXI?

Which has more risk & volatility, GLMD or ATXI?

Does the media prefer GLMD or ATXI?

Summary

How does Avenue Therapeutics compare to Virax Biolabs Group?

Does the media prefer VRAX or ATXI?

Do institutionals & insiders believe in VRAX or ATXI?

Which has more risk & volatility, VRAX or ATXI?

Is VRAX or ATXI more profitable?

Do analysts prefer VRAX or ATXI?

Which has stronger valuation & earnings, VRAX or ATXI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools